Association of autoimmune hepatobiliary pathology with inflammatory bowel diseases in children

Introduction. Hepatobiliary pathology (HBP) occurs in approximately 30% of patients with inflammatory bowel disease (IBD). However, the features of its course in the pediatric cohort of patients remain insufficiently studied. Purpose: to study the features of the course of autoimmune forms of HBD in children with IBD. Materials and methods. A comprehensive clinical, laboratory and instrumental examination was carried out in 84 children with autoimmune forms of HBP in combination with IBD (HBP+IBD), which made up the main group, and 79 patients with isolated forms of IBD included in the comparison group. Results. The prevalence of autoimmune HBP in IBD children was 10.2%. Primary sclerosing cholangitis (PSC) was diagnosed in 64.3% of cases, which was mainly associated with ulcerative colitis. The incidence of autoimmune hepatitis (AIH) was 8.3%. In the structure of the overlap syndrome, the most frequent combination was AIH+PSC (15.5%). The debut of the disease was manifested by diarrhea, abdominal pain syndrome, cytolysis and cholestasis syndromes, haemicolitis. With HBP+IBD, there was an increase in serum concentrations of alanine (ALT) and aspartate aminotransferases (AST), total protein, γ-glutamyl transferase (GGT), alkaline phosphatase, direct bilirubin and IgG. Approximately with the same frequency in PSC, antibodies to saccharomycetes (ASCA) - 80% and antibodies to the cytoplasm of neutrophils (ANCA) - 75% were detected. In AIH, antinuclear antibodies (ANA) and antibodies to liver and kidney microsomes (anti-LKM1) were detected in 100%. HBP-IBD equally (28.6%) revealed moderate fibrosis and cirrhosis, no fibrosis in 20.6%, moderate fibrosis in 15.9% of cases, mild fibrosis in 6,3%. Cirrhosis of the liver in 55.6% of cases was the outcome of the course of PSC, in 16.7% - AIH, in 27.8% was associated with the course of the overlap syndrome. Conclusion. Various forms of autoimmune HBP occur in 10.2% of cases, are more often associated with UC, are represented by PSC and AIH, occur in males, at the onset signs are clinically presented by diarrhea, abdominal pain syndrome, cytolysis and cholestasis syndromes, and haemicolitis.

[1]  A. Czajkowska,et al.  Liver Pathology in Children with Diagnosed Inflammatory Bowel Disease—A Single Center Experience , 2021, Journal of clinical medicine.

[2]  G. V. Volynets,et al.  Склерозирующий холангит и воспалительные заболевания кишечника: что первично? , 2021 .

[3]  M. Samaan,et al.  Vedolizumab-Associated Drug-Induced Liver Injury: A Case Series. , 2020, Inflammatory bowel diseases.

[4]  P. Sarzi-Puttini,et al.  EXTRA-INTESTINAL MANIFESTATIONS OF INFLAMMATORY BOWEL DISEASES. , 2020, Pharmacological research.

[5]  Eun Soo Kim,et al.  JAK Inhibitors Safety in Ulcerative Colitis: Practical Implications , 2020, Journal of Crohn's & colitis.

[6]  Q. Guan.  A Comprehensive Review and Update on the Pathogenesis of Inflammatory Bowel Disease , 2019, Journal of immunology research.

[7]  A. Fisenko,et al.  MOLECULAR DIAGNOSIS OF FIBROSIS IN DIFFUSE LIVER DISEASES , 2019, Russian Pediatric Journal.

[8]  A. Amiot,et al.  Vedolizumab therapy is ineffective for primary sclerosing cholangitis in patients with inflammatory bowel disease: A GETAID multicentre cohort study. , 2019, Journal of Crohn's & colitis.

[9]  N. Wasilewska,et al.  Hepatobiliary manifestations of inflammatory bowel disease in children , 2019, Clinical and experimental hepatology.

[10]  W. D. de Jonge,et al.  Return to sender: Lymphocyte trafficking mechanisms as contributors to primary sclerosing cholangitis. , 2019, Journal of hepatology.

[11]  N. Komarova,et al.  Differential diagnosis of various types of intrahepatic cholestasis in children with chronic liver diseases , 2019, Russian Pediatric Journal.

[12]  I. E. Smirnov,et al.  MODERN NON-INVASIVE METHODS OF DIAGNOSTICS OF LIVER FIBROSIS IN CHILDREN , 2019, Russian Pediatric Journal.

[13]  R. Chapman,et al.  The Use of Biologics in Patients with Inflammatory Bowel Disease and Primary Sclerosing Cholangitis , 2019, Current Hepatology Reports.

[14]  B. Choe,et al.  The difference in extraintestinal manifestations of inflammatory bowel disease for children and adults. , 2019, Translational pediatrics.

[15]  J. Stoker,et al.  ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications. , 2018, Journal of Crohn's & colitis.

[16]  F. Gomollón,et al.  Primary sclerosing cholangitis and inflammatory bowel disease: Intestine-liver interrelation. , 2019, Gastroenterologia y hepatologia.

[17]  L. Peyrin-Biroulet,et al.  Systematic screening for primary sclerosing cholangitis with magnetic resonance cholangiography in inflammatory bowel disease. , 2018, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[18]  T. Liwinski,et al.  Autoantibodies in Autoimmune Liver Disease—Clinical and Diagnostic Relevance , 2018, Front. Immunol..

[19]  D. Rubin,et al.  Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel disease , 2018, Alimentary pharmacology & therapeutics.

[20]  S. Itzkowitz,et al.  Inflammatory Bowel Disease and Primary Sclerosing Cholangitis: A Review of the Phenotype and Associated Specific Features , 2017, Gut and liver.

[21]  M. Wolfe,et al.  Disseminated Intravascular Coagulopathy and Newly Diagnosed Ulcerative Colitis, a Rare but Serious Complication: A Case Report: 2017 Presidential Poster Award: 1976 , 2017 .

[22]  J. Kjeldsen,et al.  Patients with inflammatory bowel disease have increased risk of autoimmune and inflammatory diseases , 2017, World journal of gastroenterology.

[23]  G. Hirschfield,et al.  EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. , 2017, Journal of hepatology.

[24]  T. Karlsen,et al.  Prevalence of Sclerosing Cholangitis Detected by Magnetic Resonance Cholangiography in Patients With Long-term Inflammatory Bowel Disease. , 2016, Gastroenterology.

[25]  S. Venkatesh,et al.  Imaging of autoimmune hepatitis and overlap syndromes , 2016, Abdominal Radiology.

[26]  Jisun Yoon,et al.  Primary Sclerosing Cholangitis with Inflammatory Bowel Disease in Korean Children , 2015, Pediatric gastroenterology, hepatology & nutrition.

[27]  K. Lazaridis,et al.  Genome-Wide Association Studies in Primary Biliary Cirrhosis , 2015, Seminars in Liver Disease.

[28]  E. DeFilippis,et al.  Clinical Presentation and Outcomes of Autoimmune Hepatitis in Inflammatory Bowel Disease , 2015, Digestive Diseases and Sciences.

[29]  Mohammad Hassan Murad,et al.  Diagnostic performance of magnetic resonance elastography in staging liver fibrosis: a systematic review and meta-analysis of individual participant data. , 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[30]  R. Weersma,et al.  Distinctive inflammatory bowel disease phenotype in primary sclerosing cholangitis. , 2015, World journal of gastroenterology.

[31]  J. Drenth.  EASL Clinical Practice Guidelines: Autoimmune hepatitis. , 2015, Journal of hepatology.

[32]  Rodrigo Liberal,et al.  Diagnostic criteria of autoimmune hepatitis. , 2014, Autoimmunity reviews.

[33]  A. Griffiths,et al.  Appraisal of the pediatric ulcerative colitis activity index (PUCAI) , 2009, Inflammatory bowel diseases.

[34]  W. Sandborn,et al.  Pediatric “PSC-IBD”: A Descriptive Report of Associated Inflammatory Bowel Disease Among Pediatric Patients With PSC , 2001, Journal of pediatric gastroenterology and nutrition.

[35]  D. Vergani,et al.  Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: A 16‐year prospective study , 2001, Hepatology.